Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Ligand for the NKG2D receptor, together with at least ULBP2 and ULBP3. Additionally we are shipping ULBP1 Kits (12) and ULBP1 Proteins (12) and many more products for this protein.
Showing 10 out of 38 products:
Human Polyclonal ULBP1 Primary Antibody for IHC, IHC (p) - ABIN4364311
de Kruijf, Sajet, van Nes, Putter, Smit, Eagle, Jafferji, Trowsdale, Liefers, van de Velde, Kuppen: NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study. in BMC cancer 2012
Show all 5 references for ABIN4364311
Mouse (Murine) Monoclonal ULBP1 Primary Antibody for FACS - ABIN4898925
Raju, Kretzmer, Koues, Payton, Oltz, Cashen, Polic, Schreiber, Shaw, Markiewicz: NKG2D-NKG2D Ligand Interaction Inhibits the Outgrowth of Naturally Arising Low-Grade B Cell Lymphoma In Vivo. in Journal of immunology (Baltimore, Md. : 1950) 2016
Show all 3 references for ABIN4898925
Human Monoclonal ULBP1 Primary Antibody for FACS - ABIN4898922
Pace, Williams, Kurioka, Gerry, Jakobsen, Klenerman, Nwokolo, Fox, Fidler, Frater: Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function. in PLoS pathogens 2016
Show all 3 references for ABIN4898922
Human Polyclonal ULBP1 Primary Antibody for WB - ABIN2783974
López-Soto, Quiñones-Lombraña, López-Arbesú, López-Larrea, González: Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor. in The Journal of biological chemistry 2006
ATF4 (show ATF4 Antibodies) drives ULBP1 gene expression in cancer cell lines, while the RNA-binding protein (show PTBP1 Antibodies) RBM4 (show RBM4 Antibodies) supports ULBP1 expression by suppressing a novel alternatively spliced isoform of ULBP1 mRNA.
expression determines intrinsic acute myeloid leukemia (show BCL11A Antibodies) susceptibility to allogeneic V[gamma]9V[delta]2 T cells
This study provides for the first time, the c-Myc (show MYC Antibodies) dependent regulation of NKG2D (show KLRK1 Antibodies) ligands, ULBP1/2/3 in acute myeloid leukemia (show BCL11A Antibodies).
recurrence-free survival of patients with ULBP1-negative hepatocellular carcinoma (HCC (show FAM126A Antibodies)) was significantly shorter than that of patients with ULBP1-positive HCC (show FAM126A Antibodies)
Findings define the involvement of p53 (show TP53 Antibodies) in the regulation of ULBP1 and ULBP2 (show ULBP2 Antibodies) which enhance NK cell-mediated target recognition.
recombinant ULBP1 fused to CD45 (show PTPRC Antibodies) caused a reduction in cytotoxicity and degranulation by NK cells, implying a role for receptor ligand distribution in the activation of NK cell responses
Data show that ULBP1, TFR2 (show TFR2 Antibodies) and IFITM1 (show IFITM1 Antibodies) were associated with increased susceptibility to Vgamma9Vdelta2 T-cell cytotoxicity.
These results identify Mult1 as a target for the MARCH family of E3 ligases
As NKG2D (show KLRK1 Antibodies) ligand, ULBP1 are expressed on immature dendritic cells and plays an important role in the cytotoxic effect of NK cells against iDC (show LMNA Antibodies).
Data show that the protease NS3/4A of HCV down-regulates ULBP1 expression by inhibiting the transcription of ULBP1.
The results show that NK cells and the NKG2D (show KLRK1 Antibodies) receptor play a role in control of lymphomas, and that selection of NKG2D (show KLRK1 Antibodies)-ligand (MULT1) loss mutants provides a mechanism for tumor escape.
An increased expression of the NKG2D (show KLRK1 Antibodies) ligand MICA (show MICA Antibodies) in systemic lupus erthematosus (SLE) patients' kidneys and Rae-1 (show RAE1 Antibodies) and Mult-1 in various murine SLE models, is reported.
MULT1 (UL16-binding protein-like transcript 1) is expressed in adult parenchyma, possesses MHC class I-like alpha 1 and alpha 2 domains and a large cytoplasmic domain, and binds NKG2D (show KLRK1 Antibodies) with high affinity. (MULT1)
Mouse cytomegalovirus (MCMV) molecule fcr-1 promotes a rapid down-regulation of NKG2D (show KLRK1 Antibodies) ligands murine UL16-binding protein like transcript (MULT)-1 and H60 from the cell surface.
ULBP1 is the predominant, if not only, functional porcine ligand for human natural killer (NK) cell activating receptor (show NCR1 Antibodies) NKG2D (show KLRK1 Antibodies); if eliminated on porcine tissues ULBP1 represents an attractive target to protect porcine xenografts from human NK cytotoxicity.
Ligand for the NKG2D receptor, together with at least ULBP2 and ULBP3. ULBPs activate multiple signaling pathways in primary NK cells, resulting in the production of cytokines and chemokines. Binding of ULBPs ligands to NKG2D induces calcium mobilization and activation of the JAK2, STAT5, ERK and PI3K kinase/Akt signal transduction pathway. In CMV infected cells, interacts with soluble CMV glycoprotein UL16. The interaction with UL16 blocked the interaction with the NKG2D receptor, providing a mechanism by which CMV infected cells might escape the immune system. UL16 also causes ULBP1 to be retained in the ER and cis- Golgi apparatus so that it does not reach the cell surface.
UL16 binding protein 1
, NKG2D ligand 1
, UL16-binding protein 1
, retinoic acid early transcript 1I
, UL16-binding protein-like transcript 1
, NK cell receptor ligand